Document Detail

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis.
MedLine Citation:
PMID:  2127787     Owner:  NLM     Status:  MEDLINE    
Eighty patients with chronic non-A, non-B hepatitis completed a randomized controlled trial of the therapeutic efficacy of recombinant interferon alfa-2b. Twenty-nine received 1 million units and 26 received 3 million units of interferon subcutaneously thrice weekly for 6 months, and 25 were controls. Normalization or a significant decrease of alanine aminotransferase values was obtained in 19/29 (66%) patients treated with 1 million units, in 18/26 (69%) patients treated with 3 million units and in one control patient (4%, p less than 0.05). However, when control patients were randomized after the initial 24 weeks to receive 1 or 3 million units of interferon for 48 weeks, 12/14 (86%) patients receiving 3 million units responded to therapy versus 3/11 patients receiving 1 million units (27%, p less than 0.05). After a 1 to 6 months follow-up period post treatment, an alanine aminotransferase relapse was observed in 18/30 (60%) responders to 3 million units and in 17/22 (77%) responders to 1 million units. Cirrhotic patients responded less than patients with non-cirrhotic disease (47 vs. 78%, p less than 0.05). Only responders treated with 3 million units significantly ameliorated their histologic picture (pre-therapy Knodell's index = 8.9, post-therapy = 6.0, p less than 0.05). The data confirm that treatment with interferon is of benefit in patients with chronic non-A, non-B hepatitis.
G Saracco; F Rosina; M R Torrani Cerenzia; V Lattore; L Chiandussi; V Gallo; R Petrino; A G De Micheli; E Donegani; A Solinas
Related Documents :
15577647 - Late presenters in the era of highly active antiretroviral therapy: uptake of and respo...
8253557 - Pilot trial of ribavirin for the treatment of laryngeal papillomatosis.
15319677 - Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz ...
17431777 - Adefovir dipivoxil alone or in combination with lamivudine for three months in patients...
10637457 - Retrospective review of flow patterns following retropubic prostatectomy.
25325267 - Clinical characteristics, management, and outcome of 22 cases of primary hypophysitis.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of hepatology     Volume:  11 Suppl 1     ISSN:  0168-8278     ISO Abbreviation:  J. Hepatol.     Publication Date:  1990  
Date Detail:
Created Date:  1991-04-30     Completed Date:  1991-04-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  S43-9     Citation Subset:  IM    
Division of Gastroenterology, Molinette Hospital, Turin, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alanine Transaminase / blood
Chronic Disease
Hepatitis C / blood,  pathology,  therapy*
Interferon Alfa-2b / therapeutic use*
Middle Aged
Reg. No./Substance:
99210-65-8/Interferon Alfa-2b; EC Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy f...
Next Document:  One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b.